ASCO GI 2026

Join Tempus at the 2026 ASCO® Gastrointestinal Cancers Symposium as we showcase our latest clinical research and to learn more about our product offerings—all designed to drive more informed, personalized care across the cancer journey.

Schedule a meeting with us

Research Highlights

Research Highlights

January 8, 2026

Time
11:30–1:00pm PT; 6:00-7:00pm PT

Presentation Number
847, J9

Authors
Michael J. Overman,
Yingying Yu,
Andreana Natalie Holowatyj,
Saikat Chowdhury,
Kanwal Pratap Singh Raghav,
Anjali Vinocha,
Paul F. Mansfield,
Beth A Helmink,
Saif Nirzhor,
Michael White,
Matina Fragkogianni,
John Paul Y.C. Shen

Genomic profiling of epithelial neoplasms of the appendix: Insights across histological subtypes and histological grades

Tempus Lens was utilized to analyze de-identified clinical genomic, and transcriptomic information for patients diagnosed with different subtypes of appendiceal epithelial neoplasms (AENs). AENs showed unique DNA alterations by histological subtype, with mutations occurring most frequently in KRAS, TP53, SMAD4, and GNAS. Grade 2 mucinous adenocarcinoma closely resembled Grade 1, not Grade 3, in survival and genomics, supporting a three-tier grading system over a high-grade (G2/G3) grouping in this subtype. Furthermore, patients with KRAS/GNAS co-mutations had better survival and a favorable immune profile in the AEN population overall, supporting further immunotherapy research in this disease.

January 9, 2026

Time
11:30–1:00pm PT; 5:00-6:00pm PT

Presentation Number
759

Authors
Maria Diab,
Brooke Rhead, Matina Fragkogianni,
Zaid Ihab Al Saheli,
Gazala Khan,
Ira S. Wollner,
Parag Parikh,
David S. Kwon,
Philip Agop Philip

Advanced pancreatic adenocarcinoma outcomes in patients with DDR deficiencies outside of BRCA1/2 and PALB2

Tempus Lens was used to analyze de-identified clinical, genomic and transcriptomic data for patients diagnosed with advanced pancreatic adenocarcinomas with mutations in the DNA damage repair (DDR) pathway other than BRCA1/2 and PALB2. We compared the outcomes of patients treated with platinum- versus non-platinum chemotherapy regimens in the first line (1L). Patients treated with platinum regimens showed a trend toward improved survival starting around 5 months of treatment (median rwOS 11.7 vs 9.8 months, p=0.471), but this was not statistically significant.

Time
11:30–1:00pm PT

Presentation Number
602

Authors
Diana L. Hanna,
Adam Dugan,
Vincent Michael Nicchi,
Young-Wook Kim,
Unnati Jariwala,
Stamatina Fragkogianni,
Jacob Mercer,
Sandra Algaze,
Heinz-Josef Lenz,
Syma Iqbal,
Anthony B. El-Khoueiry

Impact of claudin-1 (CLDN1) expression on molecular correlates and clinical outcomes in patients with advanced biliary tract cancers (BTCs)

Dysregulation of CLDN1 is associated with invasiveness and migration of cells in many cancers. We examined the molecular and clinical correlates of CLDN1 expression in a real-world cohort of patients (pts) with advanced BTCs across subtypes. We analyzed a cohort of patients with BTC who received xT and xR testing. High CLDN1 expression was associated with immune cell infiltration in this cohort of advanced BTC with improved survival in pts treated with 1L chemo+IO. Furthermore, relevant molecular alterations in BTC differed with high vs low CLDN1 expression. Larger studies are warranted to evaluate the predictive and prognostic role of CLDN1 in BTC to identify novel therapeutic strategies.

Time
11:30–1:00pm PT; 5:00-6:00pm PT

Presentation Number
784

Authors
Mustafa Raoof,
Adam Dugan,
Maurizio Pellecchia,
Allison Rosenzweig,
Loretta Erhunmwunsee,
Matina Fragkogianni,
Jacob Mercer,
Ezra E.W. Cohen,
Thatcher Heumann,
Justin H. Lo

Multiomic analysis and oncologic outcomes in pancreatic cancer by PIN1 expression

PIN1 is a novel investigational target and is associated with desmoplastic stroma, an immunosuppressive tumor immune microenvironment (TIME) and worse outcomes in pancreatic ductal adenocarcinoma (PDAC). We characterized PIN1expression and its impact on the TIME and survival in PDAC patients sequenced with xT and/or xR. Our results demonstrated that PIN1 RNA expression was higher in NLP disease sites and is associated with pro- and anti-tumor immune subsets and a favorable OS, which is contrary to previously published literature.

Time
11:30–1:00pm PT

Presentation Number
643

Authors
Udhayvir S Grewal,
Brooke Rhead,
Kayla Layng,
Katie Navo,
Stamatina Fragkogianni,
Matthew Gao,
Tao Xu,
Michael A O’Rorke, Mark E Burkard,
Seth J Concors,
Jess Maxwell,
Joseph S Dillon,
Dawn E Quelle,
Po Hien Ear,
Arvind N Dasari,
Andrew Bellizzi,
James R Howe,
Daniel M Halperin,
Chandrikha Chandrasekharan

Molecular and Immune Landscape of Early-Onset versus Average-Onset Well-Differentiated Enteropancreatic Neuroendocrine Tumors

In the current study, the authors sought to characterize the molecular and immune landscape of early (EO)- versus average-onset (AO) pancreatic (pNETs) and small intestinal NETs (siNETs) by leveraging Tempus Lens. EO pNETs exhibited a significantly lower prevalence of KRAS, TP53, SMAD4 and RB1 alterations and a higher prevalence of LRP1B alterations compared to AO pNETs. EO siNETs showed a significantly higher prevalence of PAX5 and HDAC2 alterations. EO-pNETs were significantly enriched in certain gene sets (VEGF, hedgehog signaling, myogenesis, apical junction) and depleted in others (MYC, E2F, DNA repair, G2M checkpoint), and showed enriched infiltration of M2 macrophages. The findings, from the largest analysis of its kind to date, highlight key molecular and immune differences between age sub-groups in enteropancreatic NETs, suggesting that age at diagnosis may be an important determinant of tumor biology.

Time
11:30–1:00pm; 5:00-6:00pm PT

Presentation Number
776

Molecular characterization of resected non-metastatic pancreatic cancer (PC) based on KRAS status

This study assessed whether next-generation sequencing (NGS)–based tumor profiling can guide tailoring of CT strategies in resectable pancreatic cancer (PC). Tempus Lens was used to identify PC patients sequenced with xT or xF assays. KRAS mutations did not predict survival benefit from mFOLFIRINOX or gem-nab in resected PC, however we identified distinct profiles of potentially targetable co-alterations in KRAS mutated vs. KRAS Wt patients.These findings may suggest the integration of genomic profiling in clinical trials to develop new biomarker-driven targeted strategies in the early stage disease.

Time
11:30–1:00pm; 5:00-6:00pm PT

Presentation Number
679

Authors
Binbin Zheng-Lin,
Ellen Jaeger,
Cody Eslinger,
Stamatina Fragkogianni,
Unnati Jariwala,
Arya Ashok,
Kayla Layng,
Taro Shibuki,
Daniel Ahn,
Oluseyi Abidoye,
Celine Hoyek,
Angelo Pirozzi,
Jeremy Jones,
Christina Wu,
Mitesh Borad,
Mohamad Sonbol,
John Strickler,
Takayuki Yoshino,
Masafumi Ikeda,
Tanios Bekaii-Saab

Transcriptomic Signatures of RAD51 and GATA6 Predict Improved Real-World Overall Survival with Platinum Therapy in BRCA/PALB2 Wild-Type Metastatic Pancreatic Cancer

In this study the authors postulated that BRCA/PALB2 wildtype mPC may exhibit platinum sensitivity driven by altered HRR gene expression. Tempus Lens was used to identify and analyze mPC pts with wildtype somatic BRCA1/2 and PALB2 who had Tempus xT DNA and xR RNA testing.In BRCA/PALB2wt mPC, transcriptomic profiling identified low RAD51 and high GATA6 expression as predictors for improved rwOS when treated with 1L platinum therapy. Integrating these biomarkers may improve development of DNA-damaging therapies beyond canonically defined HRD.

Authors
Kennedy Ng,
Matthew Strickland,
Sienna Durbin,
Michelle Weitz,
Adam J. Dugan,
Karyn Ronski,
Metamia Ciampricotti,
Raghav Sundar,
Sarbajit Mukherjee,
Samuel J. Klempner, MD

Coupling Tumor Genomics, Whole Transcriptome Sequencing, and Patient Outcomes to Define the Tumor Microenvironment in Receptor Tyrosine Amplified Gastrointestinal Cancers: Analysis from 24,598 Cases

Amplifications of receptor tyrosine kinases (RTKs) such as ERBB2, EGFR, MET, and FGFR2 have been previously linked to an immunosuppressive tumor microenvironment (TME). To further map TME features to tumor genomics across gastroesophageal adenocarcinoma, colorectal carcinoma, and cholangiocarcinoma, researchers utilized Tempus Lens to analyze patients with RTK-amplified and RTK non-amplified GI cancers, leveraging xT and xR testing. RTK amplifications were present in approximately 10% of all samples, consistent with known tumor-specific prevalences. These RTK-amplified tumors were also found to be enriched for MYC and CCNE1 genomic alterations and were associated with altered expression of immunosuppressive regulatory genes, including IDO1, TIM-3, and LAG3.

Schedule a meeting with us

We'll be in touch shortly.